Valuation: MediciNova, Inc.

Market Cap 66.45M 58.1M 53.62M 49.39M 93.16M 6.4B 95.2M 641M 252M 3.13B 250M 244M 10.79B P/E 2026 *
-5.19x
P/E 2027 * -3.6x
Enterprise Value 66.45M 58.1M 53.62M 49.39M 93.16M 6.4B 95.2M 641M 252M 3.13B 250M 244M 10.79B EV / Sales 2026 *
150x
EV / Sales 2027 * 166x
Free-Float
97.13%
Yield 2026 *
-
Yield 2027 * -
07-15 Medicinova Achieves Target Enrollment in Seanobi-Als Study Evaluating Mn-166 in Als Patients CI
06-08 MediciNova Receives Notice Of Allowance For New Patent Covering Use Of MN-166 In Combination With Anti-PD-1 Immune Checkpoint Inhibitor For Glioblastoma Treatment CI
06-08 MediciNova Granted US Patent Notice of Allowance for Ibudilast Combination to Treat Brain Cancer MT
05-27 MediciNova Announces Completion Of Last Patient Last Visit In The MN-001-NATG-202 Clinical Trial Of MN-001 CI
05-14 MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-16 HC Wainwright Initiates MediciNova at Buy With $10 Price Target MT
02-20 MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-30 MediciNova, Inc. Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access- Program Evaluating MN-166 in ALS Patients CI
12-30 MediciNova Inc enters $50 million equity distribution agreement with Lucid Capital Markets RE
12-18 MediciNova, Inc. Announces Completion of Patient Enrollment Evaluating MN-166 in the Prevention of Chemotherapy-Induced Peripheral Neuropathy CI
12-18 MediciNova Completes Enrollment in a Phase 2 Study of Colorectal Cancer Drug MT
12-08 MediciNova, Inc. Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 in ALS (COMBAT-ALS) in ALS Presented at the 36th International Symposium on ALS/MND CI
11-19 MediciNova, Inc. Appoints Dr. Christopher Breder, MD, Phd as Clinical and Regulatory Advisorand to Lead Scientific Advisory Board Upon Its Formation CI
1 day-4.93%
1 week-2.88%
Current month+2.27%
1 month+0.75%
3 months-7.53%
6 months-15.62%
Current year+3.05%
1 week 1.31
Extreme 1.31
1.43
1 month 1.26
Extreme 1.265
1.55
Current year 1.22
Extreme 1.22
1.92
1 year 1.17
Extreme 1.168
1.96
3 years 1.12
Extreme 1.12
2.56
5 years 1.12
Extreme 1.12
4.65
10 years 1.12
Extreme 1.12
14.5
Manager TitleAgeSince
Chief Executive Officer 76 01/08/2005
Director of Finance/CFO 49 16/06/2022
Chief Tech/Sci/R&D Officer 60 01/09/2011
Director TitleAgeSince
Chairman 76 26/09/2000
Director/Board Member 60 24/07/2019
Director/Board Member 69 01/09/2004
Date Insider Type Main position Quantity % Market Cap.
6/23/26 A Free

Director

44,500 0.0904%
6/23/26 A Free

Director

44,500 0.0904%
6/23/26 A Free

Director

44,500 0.0904%
Change 5-day change 1-year change 3-year change Capi.($)
-4.93%-2.88%+9.76%-45.12% 66.45M
-7.17%-4.39%+45.51%+79.00% 52.1B
+0.24%-1.54%+53.22%+71.85% 53.83B
+0.80%-6.31%+3.98%+423.29% 23.48B
-0.09%-0.01%-17.62%-14.67% 23.13B
-5.95%-2.58%+30.67%-9.58% 19.36B
-1.14%+0.03%+31.57%-30.42% 17.56B
-5.16%-7.00%+168.44%+306.37% 15.2B
-6.91%-5.83%+26.53%+636.97% 14.83B
+0.43%-1.03%+24.63%+191.40% 14.06B
Average -2.99%-2.65%+37.67%+160.91% 23.36B
Weighted average by Cap. -2.80%-2.36%+40.11%+144.05%

Financials

2026 *2027 *
Net sales 444K 388K 358K 330K 622K 42.7M 635K 4.28M 1.68M 20.91M 1.67M 1.63M 72M 400K 350K 323K 297K 561K 38.51M 573K 3.86M 1.52M 18.85M 1.5M 1.47M 64.94M
Net income -13.5M -11.81M -10.9M -10.04M -18.93M -1.3B -19.34M -130M -51.15M -636M -50.71M -49.59M -2.19B -22.14M -19.36M -17.87M -16.46M -31.04M -2.13B -31.72M -214M -83.88M -1.04B -83.15M -81.32M -3.59B
Net Debt - -
Logo MediciNova, Inc.
MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
Employees
6
Date Price Change Volume
17/07/26 $1.350 -4.93% 139,136
16/07/26 $1.420 +1.43% 61,625
15/07/26 $1.400 +2.19% 81,597
14/07/26 $1.370 +0.74% 15,860
13/07/26 $1.360 -2.16% 14,726
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.350USD
Average target price
9.000USD
Spread / Average Target
+566.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNOV Stock